By Lucy Parkinson, Director of Research, LSN
Orphan diseases present a unique opportunity for a biotech investor; faster development, market exclusivity and the possibility of delivering a cure to patients with no current treatment options. However, these small markets also present unique challenges in development and strategy.
At RESI San Diego, five experienced investors who specialize in rare disease opportunities will explain their strategies in the sector. These investors will explore how they identify potential in a rare disease therapeutic, and how they turn tiny markets into significant ROI.
Moderated by Ken Kengatharan, General Partner, Atheneos Capital, panelists include:
- Todd Brady, Director of Finance, Brace Pharma Capital
- Ruchita Sinha, Sr. Director of Investments, Sanofi-Genzyme Bioventures
- Lisa Beck, Executive Director, Transactions, Global Business Development, Alexion Pharmaceuticals
- Michael Henderson, Vice President, BridgeBio
Next Phase Newsletter 
Leave a comment